List of class I PI3K isoform inhibitors and their respective in vitro IC₅₀.

<p>Assays were conducted side by side with 10 µM ATP using the method described previously <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0063907#pone.0063907-Knight1" target="_blank">[22]</a>.</p

Endogenous HMGB1 released by primary rat ATII cell monolayers after scratch wounds increases alveolar epithelial wound closure via an IL-1β-dependent mechanism.

<p>(<b>A</b>) Supernatant from primary rat ATII monolayers collected 6 hours after multiple scratches (MS Cell Sup) induces an increase in the secretion of IL-1β by primary rat ATII cell monolayers via a TLR4-dependent pathway. MS Cell Sup, a blocking TLR4 antibody or its isotype control IgG were added to the monolayers after the scratch. HMGB1 was depleted from MS Cell Sup by immunoprecipitation using 30 µg/ml of HMGB1 specific Ab (MS Cell Sup IP w/HMGB1 Ab). Controls were MS Cell Sup immunoprecipitated with a control IgG (MS Cell Sup IP w/Cont Ab). IL-1β was measured by ELISA (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0063907#s2" target="_blank">methods</a>) in the cell supernatant. (<b>B</b>) IL-1β receptor antagonist (IL-1RA) prevented the MS Cell Sup-dependent increase in the rate of wound closure of primary rat ATII cell monolayers. MS Cell Sup, and IL-1β receptor antagonist (IL-1RA, 1 µg/ml) or its vehicle were added to the monolayers after the scratch. Rate of wound closure is expressed as percent of control 16 h after wounding. *<i>p</i><0.05 from monolayers exposed to condition media. **<i>p</i><0.05 from monolayers exposed to MS Cell Sup.</p

IL-1β increases wound closure via a TGF-β1-dependent mechanism in primary human ATII cell monolayers.

<p>(<b>A</b>) IL-1β increases the rate of wound closure in primary human ATII cell monolayers. IL-1β (10 ng/ml) and/or TGF-βscRII or their respective vehicles were added to the monolayers after the scratch. Phase contrast microscopy (20X magnification) immediately after wounding (left panels, t = 0 h) and after 36 h (right panels t = 36 h). Scale bar: 100 µm. (<b>B</b>) TGF-β1 soluble receptor (TGF-βscRII) prevents IL-1β-dependent increase in rate of wound closure of primary human ATII cell monolayers. IL-1β (10 ng/ml) and/or TGF-βscRII or their respective vehicles were added to the monolayers after the scratch. Rate of wound closure was expressed as percent of control 16 h after wounding. *<i>p</i><0.05 from monolayers exposed to IL-1β vehicle. **<i>p</i><0.05 from monolayers exposed to IL-1β.</p

Human recombinant HMGB1 increases alveolar epithelial wound closure via an IL-1β-dependent signaling pathway.

<p>(<b>A</b>) Human recombinant HMGB1 increases the rate of wound closure of primary rat ATII cell monolayers. HMGB1 (10 ng/ml) or its vehicle was added to the monolayers after scratch. Phase contrast microscopy (20X magnification) immediately after wounding (left panels, t = 0 h) and after 16 h (right panels t = 16 h). Scale bar: 100 µm. In some experiments, glycyrrhizin or its vehicle was added to the monolayers after the scratch. (<b>B</b>) IL-1 receptor antagonist (IL-1RA) prevents HMGB1-dependent increase in rate of wound closure of primary rat ATII cell monolayers. HMGB1 (10 ng/ml) and/or IL-1 receptor antagonist (IL-1RA, 20 µg/ml) or their respective vehicles were added to the monolayers after the scratch. Phase contrast microscopy (20X magnification) immediately after wounding (left panels, t = 0 h) and after 16 h (right panels t = 16 h). Scale bar: 100 µm. (<b>C</b>) HMGB1 increases the secretion of IL-1β by primary rat ATII cell monolayers. HMGB1 (10, 50 and 250 ng/ml, 6 h) or fully oxidized HMGB1 (ox HMGB1, 250 ng/ml) or their respective vehicles was added to the cell monolayers, and IL-1β was measured by ELISA (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0063907#s2" target="_blank">methods</a>) in the cell supernatant. In some experiments, zVAD or its vehicle was added to the cell medium 30 min prior to HMGB1. (<b>D</b>) Glycyrrhizin prevents HMGB1-dependent increase in rate of wound closure of primary rat ATII cell monolayers. (<b>E</b>) High dose of Human recombinant HMGB1 (1 µg/ml) is required to increase the rate of wound closure of 3T3 fibroblasts. HMGB1 (50, 250, 1000 ng/ml) or its vehicle was added to the monolayers after scratch. (<b>F</b>) HMGB1 does not increase the secretion of IL-1β by 3T3 fibroblasts. HMGB1 (50, 250 and 1000 ng/ml, 6 h) or its vehicle was added to the cell monolayers, and IL-1β was measured by ELISA (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0063907#s2" target="_blank">methods</a>) in the cell supernatant. IL-1β (10 ng/ml) and glycyrrhizin (20 µg/ml) or their respective vehicles were added to the monolayers after the scratch. Rate of wound closure is expressed as percent of control 16 h after wounding. *<i>p</i><0.05 from monolayers exposed to HMGB1 or IL-1β vehicles. **<i>p</i><0,005 from monolayers exposed to HMGB1.</p

TGF-β1 increases alveolar epithelial repair via PI3Kα in primary rat ATII cell monolayer.

<p>(<b>A</b>) A β6 blocking antibody (3G9) prevents IL-1β-dependent phosphorylation of Akt in primary rat ATII cell monolayers. IL-1β (10 ng/ml, 30 min) or its vehicle was added to the monolayers 30 minutes after pretreatment with a β6 blocking antibodies or its isotype control antibody (3G9, Cont IgG, 1 µg/ml). (<b>B</b>) TGF-β1 soluble receptor (TGF-βscRII) prevents IL-1β-dependent phosphorylation of Akt in primary rat ATII cell monolayers. IL-1β (10 ng/ml, 30 min) or its vehicle was added to the monolayers 30 minutes after pretreatment with a TGF-β1 soluble receptor (TGF-βscRII, 20 µg/ml) or its vehicle. (<b>C</b>) PI3 kinase inhibition prevents TGF-β1-dependent increase in rate of wound closure of primary rat ATII cell monolayers. TGF-β1 (10 ng/ml) and a broad inhibitor of PI3K (PIK90, 1 µM) or their respective vehicles were added to the monolayers after the scratch. (<b>D</b>) Inhibition of PI3Kα prevents TGF-β1-dependent increase in rate of wound closure of primary rat ATII cell monolayers. TGF-β1 (10 ng/ml) and isoform-specific inhibitors of PI3K (PW12, TGX220, SW14, 0.5 µM) or their respective vehicles were added to the monolayers after the scratch. See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0063907#pone-0063907-t001" target="_blank"><b>Table 1</b></a> for PI3K isoform-specific inhibitors IC₅₀. Rate of wound closure is expressed as percent of control 16 h after wounding. *<i>p</i><0.05 from monolayers exposed to TGF-β1 vehicle. For western blot experiments, one representative experiment is shown, three additional experiments gave comparable results; *<i>p</i><0.05 from monolayers exposed to IL-1β vehicle. For immunofluorescence experiments, one representative experiment is shown; four additional experiments gave comparable results.</p

IL-1β increases wound closure via αvβ6 integrin and TGF-β1 in primary rat ATII cell monolayers.

<p>(<b>A</b>) IL-1β increases the rate of wound closure of primary rat ATII cell monolayers. IL-1β (10 ng/ml) or its vehicle was added to the monolayers after the scratch. Phase contrast microscopy (20X magnification) immediately after wounding (left panels, t = 0 h) and after 16 h (right panels t = 16 h). Scale bar: 100 µm. (<b>B</b>) A β6 blocking antibody (3G9) prevents IL-1β-dependent increase in rate of wound closure of a primary rat ATII cell monolayer. IL-1β (10 ng/ml). A β6 blocking antibody or its isotype control antibody was added to the monolayers after the scratch. (<b>C</b>) RGD peptides prevent IL-1β-dependent increase in rate of wound closure of a primary rat ATII cell monolayers. IL-1β (10 ng/ml) and RGE or RGD peptide were added to the monolayers after the scratch. (<b>D</b>) A TGF-β1 soluble receptor (TGF-βscRII) prevents IL-1β-dependent increase in rate of wound closure of primary rat ATII cell monolayers. IL-1β (10 ng/ml) and/or TGF-βscRII or their respective vehicles were added to the monolayers after the scratch. Degree of wound closure is expressed as percent of control 16 h after wounding. *<i>p</i><0.05 from monolayers exposed to IL-1β vehicle. **<i>p</i><0.05 from monolayers exposed to IL-1β.</p

Endogenous HMGB1 released by damaged primary rat ATII cells increases alveolar epithelial wound closure.

<p>(<b>A</b>) HMGB1 was elevated in cell supernatant from rat ATII monolayers that underwent scratch wounds (MS Cell Sup) compared to cell supernatant from rat ATII monolayers that did not undergo scratch wounds (condition media). (<b>B</b>) MS Cell Sup increases the rate of wound closure of primary rat ATII cell monolayers compared to cell supernatant from rat ATII monolayers that did not undergo scratch wounds. HMGB1 was depleted from MS Cell Sup by immunoprecipitation using 30 µg/ml of HMGB1 specific Ab (MS Cell Sup IP w/HMGB1 Ab). Controls were MS Cell Sup immunoprecipitated with a control IgG (MS Cell Sup IP w/Cont Ab). (<b>C</b>) HMGB1 is secreted by primary rat ATII cell monolayers after scratch wounds. Multiple scratches (MS) were performed on primary rat ATII cell monolayers. Fresh cell media were added for 6 hours to the monolayers after extensive washes. Cell supernatants were then centrifuged to remove dead cells and cell debris, then analyzed by western blot (40 µl loaded per lanes from a 1 ml MS Cell Sup sample). (<b>D</b>) MS Cell Sup increases the rate of wound closure of a primary rat ATII cell monolayers via RAGE- and TLR4-dependent pathways, but not via a CXCR4-dependent mechanism. MS Cell Sup, and either 30 µg/ml of blocking RAGE or TLR4 antibodies or their isotype control IgG, or 1 µM of AMD3100, a CXCR4 inhibitor, were added to the monolayers after the scratch. Rate of wound closure is expressed as percent of control 16 h after wounding. *<i>p</i><0.05 from monolayers exposed to control cell media; **<i>p</i><0.05 from monolayers exposed to MS Cell Sup. For western blot experiments, one representative experiment is shown, three additional experiments gave comparable results; *<i>p</i><0.05 from monolayers exposed to condition media.</p